NCT06006832 A Prospective Cohort Study of Myasthenia Gravis in China
| NCT ID | NCT06006832 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Myasthenia Gravis |
| Study Type | OBSERVATIONAL |
| Enrollment | 202 participants |
| Start Date | 2023-08-20 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 202 participants in total. It began in 2023-08-20 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are: 1. Whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with MG. 2. To identify potential biomarkers that can predict disease progression and prognosis. This study recruits well-controlled patients with MG. Based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). Subsequently, these groups of patients will undergo long-term follow-up assessments.
Eligibility Criteria
Inclusion Criteria: * 1: Attended the outpatient department of neurology of PUMCH from 9/30/2022 to 9/30/2024. * 2: Diagnosed as myasthenia gravis. * 3: Follow-up time at PUMCH\>6 months. * 4: The patient understood and signed the informed consent form. Exclusion Criteria: * 1: Comorbidities with other conditions that cause skeletal muscle weakness make the clinical symptoms difficult to assess * 2: Records related to comorbidities and medications were not available at baseline and during follow-up.
Contact & Investigator
Yuzhou Guan
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06006832 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myasthenia Gravis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06006832 currently recruiting?
Yes, NCT06006832 is actively recruiting participants. Contact the research team at guanyz001@163.com for enrollment information.
Where is the NCT06006832 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06006832 clinical trial?
NCT06006832 is sponsored by Peking Union Medical College Hospital. The principal investigator is Yuzhou Guan at Peking Union Medical College Hospital. The trial plans to enroll 202 participants.